AP
MRTX

Advisors Preferred’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Advisors Preferred’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-385
Closed -$6K – 446
2013
Q4 		$6K Buy
+385
New +$6.58K ﹤0.01% 350

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisors Preferred's MRTX Position: Q1 2014 in Review

Advisors Preferred sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2014, closing a stake of 385 shares — an estimated $6K sold.

Advisors Preferred first reported a position in MRTX in Q4 2013 and held it in 1 quarter. The position peaked at $6K in Q4 2013. 33 funds tracked by Wall St. Rank hold MRTX as of Q1 2014.

  • Advisors Preferred reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • Advisors Preferred sold 385 Mirati Therapeutics, Inc. Common Stock shares in Q1 2014, an estimated $6K.
  • Advisors Preferred first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2013 and held it in 1 quarter.
  • Advisors Preferred's Mirati Therapeutics, Inc. Common Stock position peaked at $6K in Q4 2013.
  • 33 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2014.

Based on Advisors Preferred's 13F filing for Q1 2014, filed 14 May 2014.